Opioid

Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Quality of life, Pain management, ATX, Perioperative, Pain, LLP, Therapy, Opioid, TKA, Patient, Cooley LLP

Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.

Key Points: 
  • Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
  • Allay retains the right to develop and commercialize ATX101 in all territories outside of Japan.
  • "Maruishi is one of the leading specialty pharmaceutical companies in perioperative care and anesthetic settings, with strong development and commercial capabilities within the acute post-operative pain management arena,” said Adam Gridley, Chief Executive Officer of Allay.
  • "We’re especially excited to partner with Maruishi given their similar mission to improve quality of life and ease post-surgical recovery.

CALIFORNIA BAY AREA YOUTH USE FASHION, MUSIC, AND ART TO ADDRESS VIOLENCE

Retrieved on: 
Tuesday, December 26, 2023
Opioid, Lead, Music, Hatred, SAN, California State University, Celebration, African Americans, Volunteering, Self-care, Tech, Bullying, Entrepreneurship, Nightclub

Event at Napredak Hall (770 Montague Expressway) in San Jose, Ca, Stop The Violence east Bay Event at California State University East Bay on February 24th, and the Stop The Violence San Mateo County/SF event on March 30, location tba.

Key Points: 
  • Event at Napredak Hall (770 Montague Expressway) in San Jose, Ca, Stop The Violence east Bay Event at California State University East Bay on February 24th, and the Stop The Violence San Mateo County/SF event on March 30, location tba.
  • Each event features a fashion show, talent show, speakers, and raises money for youth to create and lead service projects that address violence, hate, and bullying.
  • Youth will have the ability to represent the Bay Area at the Los Angeles Stop The Violence Event.
  • Youth, 12-24, can sign up to participate, and companies can get involved to serve as volunteers and champions for each youth event.

IMPROVLearning Calls for Nationwide Action to Combat Rising U.S. Traffic Deaths

Retrieved on: 
Friday, December 22, 2023
Opioid, Safety, Culture, Behavior, Risk, Death, Education

ENCINO, Calif., Dec. 22, 2023 /PRNewswire-PRWeb/ -- In light of the alarming insights presented by David Leonhardt in his New York Times article, "The Rise in U.S. Traffic Deaths," IMPROVLearning urgently calls for a nationwide initiative to improve driver safety through enhanced training and awareness. This call to action comes in response to America's escalating problem with vehicle crashes and traffic fatalities.

Key Points: 
  • This call to action comes in response to America's escalating problem with vehicle crashes and traffic fatalities.
  • Unlike other high-income countries, where vehicle deaths continue to decrease, the U.S. faces a unique challenge with a rising death toll.
  • According to the article, if the U.S. had matched the progress of other nations, approximately 25,000 fewer Americans would die in traffic incidents each year.
  • IMPROVLearning is committed to leading the charge in promoting safe driving practices through its comprehensive driver training programs .

Arkansas Children's Establishes $70 Million Groundbreaking Center Focused on Opioids' Impact on Children

Retrieved on: 
Thursday, November 9, 2023
Arkansas Department of Health, Arkansas Children's Hospital, Brain, ESC, Research, Opioid, Fentanyl, NICU, Pediatrics, USDA, Substance abuse, Toxicology, Arkansas Department of Corrections, Learning, Informatics, History, Pregnancy, Journal, Map, Machine learning, Poisoning, Heroin, Health, Child, Birth, NCOR, School, Mother, Alcohol withdrawal syndrome, Social work, Hospital, The Journal of Pediatrics, Fetus, ROCK, Initiative, Face, Research institute, Pharmaceutical industry, Vaccine, Nursing, Birth control

LITTLE ROCK, Ark., Nov. 9, 2023 /PRNewswire/ -- Arkansas Attorney General Tim Griffin is awarding $50 million of opioid settlement funds to Arkansas Children's to pioneer one of the nation's most ambitious research efforts dedicated to opioids' impact on children.

Key Points: 
  • I am granting $50 million of the state's opioid settlement funds to help establish the National Center for Opioid Research & Clinical Effectiveness (NCOR) at Arkansas Children's.
  • "This research center will be the first of its kind not just in Arkansas, but in the entire country.
  • "By creating this center, we are accelerating a healthier future for the children of Arkansas.
  • Scientists will work closely with the Arkansas Children's Research Institute and Arkansas Children's Nutrition Center, one of six National Human Nutrition Centers funded through the USDA-ARS.

Fentanyl.org Launches Platform Providing Real Time Help - Get Reliable Information About Fentanyl & Synthetic Opioids Comprehensive Directory of Treatment & Opiate Detox Options

Retrieved on: 
Wednesday, November 8, 2023
Opioid, Parent, Morphine, DEA, Heroin, Skin, Death, Oxycodone, Drug, Fentanyl, Adderall

COMMACK, N.Y., Nov. 8, 2023 /PRNewswire/ -- Fentanyl kills more people in the USA than have died in wars. It is so deadly that even inhaling it can cause death First responders have died from coming into contact with it, as it is easily absorbed through the skin. Fentanyl comes into the USA from the land, sea and air borders. The nations youth are dying in record numbers from Fentanyl Laced counterfeit street drugs.

Key Points: 
  • Over 300 Americans die every day from overdoses related to synthetic opioids like fentanyl.
  • Fentanyl is a synthetic opioid that is up to 50X stronger than heroin and 100X stronger than morphine.
  • Fentanyl is commonly used to create counterfeit drugs sold on the street as OxyContin, Xanax, Adderall, and other pills.
  • In 2022, the DEA seized more than 58.3 million pills containing fentanyl and more than 13,000 pounds of fentanyl powder.

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Retrieved on: 
Monday, November 6, 2023
MRI, Biomarker, Physician, Low back pain, Neurosurgery, Regeneration, KOL, Surgeon, ACON, Opioid, Algorithm, Magnetic resonance imaging, Spine, CO, Pain, Degenerative disc disease, Diagnosis, Patient, Software as a service, Hospital, Medical imaging, Medical device

BROOMFIELD, CO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Roger Hartl, M.D., Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, as well as the co-director of New York-Presbyterian Och Spine, will advise the company as a key opinion leader (KOL) nationally.

Key Points: 
  • Aclarion will report on Nociscan volumes to date before the end of the year and add this key metric to quarterly reporting beginning in 2024.
  • Dr. Hartl's practice emphasizes an interdisciplinary approach to disease processes, and he works very closely with other specialists to personalize patient treatments.
  • I expect Nociscan will provide valuable, objective information to our interdisciplinary approach for treating degenerative disc disease.
  • For information about Nociscan use in New York City, please contact Aclarion at [email protected] .

Aclarion Presents at the NIH HEAL Initiative Fall Meeting

Retrieved on: 
Wednesday, November 1, 2023
Trial of the century, BEST, Biomarker, Physician, Comeback, BACPAC, Clinical trial, ACON, Opioid, NIH, Algorithm, Initiative, CO, Patient, Software as a service, Dentistry, Medical imaging, Online shopping

BROOMFIELD, CO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan decision support tool will be presented at the 2023 Fall Meeting for the NIH HEAL Initiative BACPAC Research Program on November 1-2, 2023. Aclarion will be presenting Nociscan, the first, evidence-supported , SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan is being utilized in the two leading low back pain trials within the HEAL Initiative – comeBACK and BEST.

Key Points: 
  • The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research.
  • The Back Pain Consortium (BACPAC) Research Program, a recipient of the NIH HEAL Initiative, is an effort to address the need for effective and personalized therapies for chronic low back pain (cLBP).
  • Nociscan is being utilized in the two leading low back pain trials within the HEAL Initiative – comeBACK and BEST.
  • Chronic low back pain (cLBP) is a leading cause of opioid addiction in the U.S., and the NIH is addressing the opioid crisis through this initiative.

SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology

Retrieved on: 
Tuesday, October 31, 2023
Combination, Patent, Chronic pain, TEL, IP Australia, Legislation, Pain, Market, Route of administration, Opioid, Disorder, Intrathecal administration, Patient, Central nervous system, Pharmaceutical industry, Anesthesia

The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents.
  • The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected to drive market growth.
  • At the same time, opioid abuse and addiction has been a global growing epidemic for more than a decade.
  • "The fact that SciSparc's number of granted patents continues to grow is proof recognizing the innovation that characterizes the technologies in the Company's pipeline.

Jolly Good Inc. Establishes North American Subsidiary: Joint Development of Medical VR for "Apple Vision Pro" with U.S. Experts

Retrieved on: 
Wednesday, November 1, 2023
A Jolly Good Fellow (novel), Post-traumatic stress disorder, Anxiety, VR, Cognitive behavioral therapy, Johns Hopkins University, University of Oxford, Chronic pain, United States Department of Veterans Affairs, Boston University Chobanian & Avedisian School of Medicine, SCI, Veterans' affairs, QOL, Veteran, University of Bath Department of Psychology, Opioid use disorder, Research, Chūō-ku, State, Death, PTSD, Quality of life, Learning, Feel Good Inc., Psychology, Boston University School of Public Health, Teaching, Boston University, Apple, Pain, DSM-IV codes, Eye, Opioid, CBT, Cancer, Pain management, Behavioral medicine, Patient, Doctor of Philosophy, Poultry farming, Video game, Nursing, Pharmaceutical industry, Dentistry, Neuroscience

TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.

Key Points: 
  • Chronic Pain Experts
    TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North American subsidiary with a view to further business expansion in North America.
  • In North America, we will also focus on development for spatial computing, including "Apple Vision Pro" (*1), in both its digital therapy VR and medical education VR businesses.
  • Opioid abuse and addiction are currently a major social problem in the United States, and many people who take them experience chronic pain.
  • Through this experience, we aim to provide medical education and mental illness treatment using live-action 360-degree video, which is a feature of Jolly Good.

America Finds Its Partner in Combating the Opioid Crisis and Chronic Pain with the Launch of Predictive Health Company Outcomeus

Retrieved on: 
Wednesday, October 25, 2023
Pain, Health, Chronic pain, Elective surgery, Medicare, Opioid, Common, Medicaid, Octane, Pain management, Patient, Cardiovascular disease, Nursing, Pharmaceutical industry

Irvine, California--(Newsfile Corp. - October 25, 2023) - Today at the annual OCTANe Medical Innovation Forum, award-winning executive and social entrepreneur Brian Meshkin announced the launch of predictive health company Outcomeus. Meshkin, who was previously selected as OCTANe's CEO of the Year, detailed to attendees how Outcomeus helps to solve America's dueling public health crises: its most prevalent and expensive health condition-chronic pain-and its most dire preventable cause of death-opioid overdose. Outcomeus is led by a team of proven executives and researchers in the fields of predictive health and chronic pain management. The company's clinical services and proprietary Doality Platform are powered by the world's largest clinical data bank for pain and orthopedics, with over 153,000 patients and 28 billion data points.

Key Points: 
  • The recent launch of predictive health company Outcomeus marks a meaningful advance in America's ongoing fight against opioid overdoses and chronic pain.
  • Irvine, California--(Newsfile Corp. - October 25, 2023) - Today at the annual OCTANe Medical Innovation Forum , award-winning executive and social entrepreneur Brian Meshkin announced the launch of predictive health company Outcomeus .
  • Outcomeus is led by a team of proven executives and researchers in the fields of predictive health and chronic pain management.
  • Using Outcomeus's monthly monitored predictive insights, patients achieved a near 50% reduction in pain within 30 days, which sustained for months.